The following information is furnished pursuant to both Item 2.02 and Item 7.01.

On September 25, 2006, AngioDynamics, Inc. issued a press release announcing its financial results for the thirteen weeks ended September 2, 2006. A copy of the release is attached hereto as Exhibit 99.1 and is incorporated herein by reference in its entirety.

2

reflecting particular strength in sales of the Morpheus CT PICC. Sales of venous products were $2.7 million in the quarter, up 27%, or $570,000, with VenaCure® procedure kit sales increasing 25% over the prior-year quarter. Sales of thrombolytic products were $1.2 million, up 28%, or $260,000, with sales of the Uni*Fuse™ catheter growing at 34%. PTA products had sales of $1.1 million, an increase of 10%, or $100,000, over sales from the first quarter of fiscal 2006.

Gross profit increased 25% to $11.9 million for the fiscal 2007 first quarter from $9.5 million for the prior-year first quarter, and the gross margin rose to 58.9% from 58.2% last year, a 70 basis point improvement. These increases were primarily due to a favorable product mix comprising higher-margin products including the Total Abscession drainage catheter.

Operating profit for the fiscal 2007 first quarter declined to $1.8 million from $1.9 million for the prior-year first quarter. The operating profit for the first quarter of 2007 includes additional stock-based compensation expense primarily from the Company’s adoption of SFAS 123R of $488,000, which was not included in the prior fiscal year. Additionally, the Company experienced non-recurring legal and consulting charges of $200,000. Excluding the effect of SFAS 123R and one-time expenses, operating profit would be $2.5 million, or an increase of 31%, over the 2006 first quarter.

Other income for the fiscal 2007 first quarter was $1.2 million, primarily generated from interest income on the proceeds of a public stock offering completed during the last quarter of fiscal 2006.

The Company’s effective tax rate for the fiscal 2007 first quarter was 37%, compared with a tax rate of 38% for the prior-year period. The decrease is attributable to tax-exempt interest income earned on municipal bonds.

Net income in the first quarter of fiscal 2007 was $1.9 million, or $0.12 per diluted share, an increase of $606,000 from the fiscal 2006 quarter, or 47%. Without the impact of the adoption of SFAS 123R, net income would be $2.2 million, or $0.14 per diluted share, an increase of 72% from the prior year.

Eamonn P. Hobbs, president and chief executive officer of AngioDynamics, commented, “This has been an excellent quarter whereby we demonstrated our ability to grow core products at a double-digit rate and drive earnings growth through gross margin improvement. Additionally, we continue to add to our R&D portfolio and recently purchased vascular access port technology, which we will seek to commercialize in a new vascular access port that addresses the shortcomings of currently available products.”

Mr. Hobbs continued, “Although many of our products posted solid growth during the quarter, our higher-margin Total Abscession catheter stands out as an example of an innovative product that has become a top performer with year-over-year sales growth of 171%. The Total Abscession catheter is a general purpose drainage catheter with a one-of-a-kind, tamper-proof locking mechanism named ‘The VAULT^TM.’ It was launched to the full market in December 2005, and since then has steadily gained a significant foothold in the drainage market due to its versatility and valuable features.”

AngioDynamics had cash and investments totaling $89.2 million as of September 2, 2006, compared with $89.8 million as of June 3, 2006.